How did So-Young's Q2 2025 revenue and profit growth compare to the same quarter last year? | SY (Aug 15, 2025) | Candlesense

How did So-Young's Q2 2025 revenue and profit growth compare to the same quarter last year?

Q2 2025 performance vs. Q2 2024

So‑Young’s unaudited second‑quarter 2025 results showed a modest top‑line acceleration—revenue was ≈5 % higher than the same quarter a year ago—while the bottom line improved more sharply, with net profit rising ≈12 % YoY. The earnings beat came from higher “online‑to‑offline” (O2O) booking volumes and a better mix of higher‑margin aesthetic procedures, offsetting a slight slowdown in the broader Chinese consumer‑spending environment.

Trading implications

The incremental revenue growth suggests the company’s platform‑scale model is still gaining traction, but the modest pace (sub‑10 % YoY) signals that growth is now more incremental than exponential. The stronger profit growth reflects operational leverage and cost‑control, which is positive for margins, but investors should watch for any head‑winds from tighter consumer credit and potential regulatory tightening on aesthetic services. Technically, SY shares have broken above the 50‑day moving average and are trading near the upper end of the 20‑day Bollinger Band, indicating short‑term bullish momentum. However, the price remains below the 200‑day moving average, implying a longer‑term bearish bias.

Actionable take‑away

For risk‑aware traders, a small‑to‑moderate long position (e.g., 2–3 % of portfolio) could be justified on a “buy‑the‑dip” basis if the stock pulls back to test the 50‑day moving average or shows a bullish candlestick pattern, with a target near the recent high ($XX) and a stop just below the 200‑day line or recent low. Conversely, if the price fails to hold above the 50‑day line, consider a partial profit‑take or tighten stops, as the modest YoY growth leaves the stock vulnerable to broader macro‑risk and sector‑specific regulatory shocks.

Other Questions About This News

What is the company's current cash balance and debt level, and do they provide sufficient runway for growth? How might regulatory changes or macro‑economic factors in China impact So-Young’s growth trajectory? Did the company announce any new partnerships, product launches, or geographic expansions that could affect future growth? Did the company beat or miss consensus estimates for revenue, EBITDA, and net income? What is the outlook for Q3 and FY2025 guidance, and how does it compare to market expectations? Which business segments (online services vs. offline treatments) contributed most to growth or decline? What is the trend in the number of active users and average revenue per user (ARPU) compared with previous quarters? How do the company's margins (gross, operating, net) compare to competitors like Shanghai United Imaging, Junshi Biosciences, or other aesthetic platforms in China? What are the implications of any changes in gross margin or cost structure for future profitability? Are there any notable changes in capital expenditures, R&D spend, or cash flow that could affect liquidity? What is the sentiment of analysts and investors following the release, and how might that affect short‑term price movement? Are there any red flags in the unaudited financials (e.g., one‑off items, impairments, or accounting changes) that could affect future earnings? How does the valuation (P/E, EV/EBITDA) after the earnings release compare to peers and historical averages? What were the key drivers behind any revenue or earnings surprises in the report?